Long-term weight loss with DSM's Fabuless

3 June 2007

A recent clinical trial suggests that daily consumption of yogurt containing Dutch firm DSM's satiety ingredient Fabuless significantly aids weight maintenance after weight loss. The placebo-controlled, double-blind test aimed to investigate the long-term effects of the agent on a group of women aged 18-55 and the results, which appeared in the Journal of Obesity, show that it successfully reduces appetite and weight gain after dieting.

Fabuless is a patent-protected combination of naturally-occurring oat and palm oils formulated in a novel emulsion. The microstructure of Fabuless is thought to prevent the digestion of palm oil droplets until relatively deep in the small intestine. Undigested fat arriving in the latter part of the small intestine triggers a satiety signal. Because they feel no need to take in more calories, consumers can eat less but still feel satisfied, DSM noted.

In the study, conducted by researchers at the Netherlands' University of Maastricht, 50 overweight females underwent a six-week weight loss period, followed by 18 weeks weight maintenance. During the weight maintenance phase, they consumed yogurt containing either Fabuless or placebo. Those who consumed Fabuless showed no significant regain in body weight after six weeks of dieting. This was in contrast to the placebo group, which experienced significant weight gain.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK







Today's issue

Company Spotlight